Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Short term Debt: 2020-2021

  • Whitehawk Therapeutics' Short term Debt fell 98.20% to $258,000 in Q4 2021 from the same period last year, while for Dec 2021 it was $258,000, marking a year-over-year decrease of 98.20%. This contributed to the annual value of $258,000 for FY2021, which is 98.20% down from last year.
  • As of Q4 2021, Whitehawk Therapeutics' Short term Debt stood at $258,000, which was up 1,072.73% from $22,000 recorded in Q3 2021.
  • In the past 5 years, Whitehawk Therapeutics' Short term Debt ranged from a high of $14.3 million in Q4 2020 and a low of $22,000 during Q3 2021.
  • Over the past 2 years, Whitehawk Therapeutics' median Short term Debt value was $258,000 (recorded in 2021), while the average stood at $4.9 million.
  • Data for Whitehawk Therapeutics' Short term Debt shows a maximum YoY crashed of 98.20% (in 2021) over the last 5 years.
  • Quarterly analysis of 2 years shows Whitehawk Therapeutics' Short term Debt stood at $14.3 million in 2020, then tumbled by 98.20% to $258,000 in 2021.
  • Its last three reported values are $258,000 in Q4 2021, $22,000 for Q3 2021, and $14.3 million during Q4 2020.